Abstract
Glucuronide prodrugs have shown promising efficacy in anti-cancer therapy due to their increased specificity and reduced systemic toxicity. The prodrugs can be used in prodrug monotherapy (PMT), which is based on elevated tumor β-glucuronidase activity. β-Glucuronidase activates the low-toxic prodrugs into highly cytotoxic agents specifically in the tumor site. The specificity of the prodrugs can be further improved by combined use with monoclonal antibodies against tumor-specific antigens, namely antibody-directed enzyme prodrug therapy (ADEPT); and the potency of the prodrugs can be greatly enhanced with the incorporation of an appropriate radionuclide in the combined chemo- and radio-therapy of cancer (CCRTC) strategy. The prodrugs can also be utilized to modify liposomes for efficient delivery of anti-cancer drugs.
Original language | English (US) |
---|---|
Pages (from-to) | 139-150 |
Number of pages | 12 |
Journal | Current Medicinal Chemistry - Anti-Cancer Agents |
Volume | 3 |
Issue number | 2 |
DOIs | |
State | Published - 2003 |
Externally published | Yes |
ASJC Scopus subject areas
- Molecular Medicine
- Cancer Research
- Pharmacology